0000899243-20-031922.txt : 20201123
0000899243-20-031922.hdr.sgml : 20201123
20201123164716
ACCESSION NUMBER: 0000899243-20-031922
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201119
FILED AS OF DATE: 20201123
DATE AS OF CHANGE: 20201123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dallas Jayson Donald Alexander
CENTRAL INDEX KEY: 0001650322
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39655
FILM NUMBER: 201338363
MAIL ADDRESS:
STREET 1: AIMMUNE THERAPEUTICS, INC.
STREET 2: 8000 MARINA BOULEVARD, SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Galecto, Inc.
CENTRAL INDEX KEY: 0001800315
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 371957007
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: GALECTO BIOTECH AB
STREET 2: OLE MAALOES VEJ3
CITY: COPENHAGEN
STATE: G7
ZIP: DK-2200
BUSINESS PHONE: 45-70-70-52-10
MAIL ADDRESS:
STREET 1: GALECTO BIOTECH AB
STREET 2: OLE MAALOES VEJ3
CITY: COPENHAGEN
STATE: G7
ZIP: DK-2200
FORMER COMPANY:
FORMER CONFORMED NAME: Galecto Inc.
DATE OF NAME CHANGE: 20200116
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-19
0
0001800315
Galecto, Inc.
GLTO
0001650322
Dallas Jayson Donald Alexander
C/O GALECTO, INC.
OLE MAALOES VEJ 3
COPENHAGEN N
G7
DK-2200
DENMARK
1
0
0
0
Stock Option (right to buy)
16.60
2020-11-19
4
A
0
18000
0.00
A
2030-11-18
Common Stock
18000
18000
D
Stock Option (right to buy)
16.60
2020-11-19
4
A
0
9000
0.00
A
2030-11-18
Common Stock
9000
9000
D
The shares subject to such option vest in 36 equal monthly installments over three years from the date of vesting commencement of November 19, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date.
Represents a pro-rated annual option grant to a non-employee director upon appointment to the Board of Directors of the Company. The shares subject to such option vest in twelve equal monthly installments, commencing on November 19, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date.
/s/ Jonathan Freve, attorney-in-fact
2020-11-23